Description

10x Genomics: Expanding Footprint Within Biopharma Sector To Shape Their Future! 

10x Genomics, a pioneer in single-cell and spatial transcriptomics, recently released its financial results for Q4 and the full year 2024. The company experienced a 1% decrease in total revenue year-over-year, ending with $611 million. This was largely due to challenges stemming from macroeconomic conditions and significant changes within the company. On a positive note, 10x Genomics made substantial strides in product innovation with major launches across all three of its platforms: Chromium, Visium, and Xenium. These new products have been positively received by customers, contributing to significant increases in spatial consumable revenue, which grew 61% in Q4 alone. The launch of the GEM-X architecture and other cost-effective assays on the Chromium platform has set new standards for price per cell, supporting the company’s efforts to democratize single-cell analysis. However, these launches led to lower average pricing per reaction, which offset the volume growth and impacted Chromium consumable revenue negatively, resulting in a 17% decline in Q4.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!